<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of anticoagulants in patients undergoing endoscopic procedures</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of anticoagulants in patients undergoing endoscopic procedures</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of anticoagulants in patients undergoing endoscopic procedures</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick S Kamath, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen M Robson, MD, MBA, FACG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Management of anticoagulation in patients undergoing endoscopic procedures is challenging because interrupting anticoagulation for a procedure transiently increases the risk of thromboembolism. At the same time, some endoscopic interventions have associated bleeding risks that are increased by the anticoagulant administered for thromboembolism prevention. In addition, limited data are available to guide the management of anticoagulated patients in these settings.</p><p>This topic will review periprocedural management of patients taking anticoagulants. The management of patients taking antiplatelet agents, as well as patients with von Willebrand disease, hemophilia, and other disorders of hemostasis are discussed separately. (See  <a class="medical medical_review" href="/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a>.)</p><p>Additional details regarding the use of specific anticoagulants are presented separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Vitamin K antagonists (see  <a class="medical medical_review" href="/d/html/1334.html" rel="external">"Warfarin and other VKAs: Dosing and adverse effects"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heparins (see  <a class="medical medical_review" href="/d/html/1348.html" rel="external">"Heparin and LMW heparin: Dosing and adverse effects"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Direct oral anticoagulants (direct thrombin inhibitors [<a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>] and direct factor Xa inhibitors [<a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>]) (see  <a class="medical medical_review" href="/d/html/1370.html" rel="external">"Direct oral anticoagulants (DOACs) and parenteral direct-acting anticoagulants: Dosing and adverse effects"</a>).</p><p></p><p>Recommendations for patients with prosthetic heart valves are discussed separately. (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p>The American Society for Gastrointestinal Endoscopy (ASGE) has issued guidelines regarding the management of patients taking anticoagulants based upon the available evidence and consensus opinion [<a href="#rid1">1</a>]. The recommendations in this topic are consistent with ASGE guidelines. This topic is also addressed in an international consensus statement and in guidelines from the American College of Gastroenterology, the American College of Chest Physicians, the American College of Cardiology, and the British Society of Gastroenterology/European Society of Gastrointestinal Endoscopy, which make similar (though not identical) recommendations [<a href="#rid2">2-6</a>]. </p><p class="headingAnchor" id="H236826215"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H2245295641"><span class="h2">Factors that guide decision-making</span><span class="headingEndMark"> — </span>The management of anticoagulated patients undergoing endoscopy takes into account the patient’s risk of thrombosis, the procedure-related bleeding risk, and the specific features of the anticoagulant that the patient is taking [<a href="#rid7">7,8</a>]. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Overview of our approach'</a>.)</p><p>Much of our approach is based on expert opinion; thrombotic and bleeding risks may vary depending on individual circumstances, and data from randomized trials or well-designed observational studies are not available to guide practice in all settings. In addition, the best surrogate for complete resolution of anticoagulant effect is not always known or available for the direct oral anticoagulants. Thus, this approach should be used as clinical guidance and should not substitute for clinician judgment in decisions about periprocedural anticoagulation management [<a href="#rid7">7-9</a>].</p><p class="headingAnchor" id="H1787925205"><span class="h2">Assess risk</span><span class="headingEndMark"> — </span>Interruption of anticoagulation temporarily increases thromboembolic risk, while continuing anticoagulation increases the risk of bleeding associated with invasive procedures; both of these outcomes adversely affect mortality [<a href="#rid9">9</a>]: </p><p class="headingAnchor" id="H1461614591"><span class="h3">Estimate thromboembolic risk</span><span class="headingEndMark"> — </span>The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation depends upon the pre-existing condition for which the medication was prescribed. A higher thromboembolic risk increases the importance of minimizing the time interval without anticoagulation. For example, common conditions that increase thromboembolic risk include atrial fibrillation and venous thromboembolism  (<a class="graphic graphic_table graphicRef86930" href="/d/graphic/86930.html" rel="external">table 1</a>). Further details on estimating the risk of thromboembolism are discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Estimating thromboembolic risk'</a>.)</p><p>Recommendations for patients with prosthetic heart valves are discussed separately. (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p>In UpToDate topics, the categories for thrombotic risk are listed as "moderate, high and very high", although other publications and guidelines list similar categories as "low, moderate (or medium), and high" [<a href="#rid1">1,3</a>]. Therefore, in this topic, patients in the "low or moderate risk" category are similar to patients in the "low risk" category in other publications. </p><p>Similarly, the "high risk" category in this topic includes any of the following groups: patients in the "high risk" category (by any classification system), patients in the "very high" category in UpToDate, and patients in the "moderate risk" category in other publications [<a href="#rid1">1,3</a>]. (See <a class="local">'Patients with low to moderate thrombotic risk'</a> below and <a class="local">'Patients with high thrombotic risk'</a> below.)</p><p class="headingAnchor" id="H3176604593"><span class="h3">Estimate bleeding risk</span><span class="headingEndMark"> — </span>The risk of bleeding depends on the endoscopic procedure and the need for (and type of) therapeutic intervention. (See  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Estimating procedure-related bleeding risk'</a>.)</p><p>Common low-risk procedures (bleeding risk &lt;1 percent) include  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Upper gastrointestinal endoscopy (esophagogastroduodenoscopy [EGD]) including mucosal biopsy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy including mucosal biopsy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Endoscopic retrograde cholangiopancreatography (ERCP) without sphincterotomy</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary stent placement</p><p></p><p>Common high-risk procedures (bleeding risk ≥1 percent) include:</p><p class="bulletIndent1"><span class="glyph">●</span>EGD with esophageal variceal ligation</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>EGD with esophageal dilation </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous endoscopic gastrostomy tube placement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Colonoscopy with polypectomy of large polyp (≥1 cm)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ERCP with biliary or pancreatic sphincterotomy</p><p></p><p>The approach to managing anticoagulation depends on whether the procedure is low or high risk for bleeding. (See <a class="local">'Elective procedures'</a> below.)</p><p>For some procedures (eg, screening colonoscopy), the preprocedure estimate of bleeding risk is uncertain because it is unknown whether a high-risk intervention (eg, polypectomy of large polyp [≥1 cm]) will be necessary. For patients undergoing a procedure with uncertain risk, management options depend on the patient’s risk of thrombosis, the specific anticoagulant, and patient preference. Our approach (and alternatives) in this setting are discussed separately for patients with low to moderate thrombotic risk (see <a class="local">'High or uncertain risk procedures'</a> below) and for patients with high thrombotic risk (see <a class="local">'Procedures with uncertain risk'</a> below). </p><p class="headingAnchor" id="H2195270299"><span class="h2">Specialty consultation</span><span class="headingEndMark"> — </span>We consult with the clinician and/or clinical service who are managing the patient’s long-term anticoagulation (eg, cardiologist, neurologist, anticoagulation clinic) prior to electively interrupting anticoagulation therapy.</p><p class="headingAnchor" id="H5"><span class="h1">ELECTIVE PROCEDURES</span></p><p class="headingAnchor" id="H1348831224"><span class="h2">Patients with low to moderate thrombotic risk</span><span class="headingEndMark"> — </span>Examples of conditions that confer a low or moderate thrombotic risk include  (<a class="graphic graphic_table graphicRef86930" href="/d/graphic/86930.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation and a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 2 to 3 or CHADS<sub>2</sub> score of zero to 2 (assuming no prior stroke or transient ischemic attack)  (<a class="graphic graphic_table graphicRef94752" href="/d/graphic/94752.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism &gt;12 months previous and no other risk factors</p><p></p><p class="headingAnchor" id="H6"><span class="h3">Low risk procedures</span><span class="headingEndMark"> — </span>Patients at low or moderate risk for thrombosis require no change in anticoagulation prior to low-risk procedures  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>) (eg, upper gastrointestinal endoscopy [esophagogastroduodenoscopy [EGD] or colonoscopy, including mucosal biopsy)  (<a class="graphic graphic_algorithm graphicRef119161" href="/d/graphic/119161.html" rel="external">algorithm 1</a>). However, for most patients scheduled for screening colonoscopy, the bleeding risk is uncertain because it is unknown whether or not polypectomy of a large polyp (≥1 cm) will be needed. Our approach to management in this setting is described below. (See <a class="local">'High or uncertain risk procedures'</a> below.) </p><p>If the international normalized ratio (INR) is &gt;2.5, we postpone elective procedures for patients taking vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) until the INR is ≤2.5. The threshold INR value is based on indirect data in patients undergoing endoscopic procedures for active bleeding and the endoscopist’s personal preference, while other experts may use different thresholds. (See <a class="local">'Patients on warfarin'</a> below.)</p><p class="headingAnchor" id="H7"><span class="h3">High or uncertain risk procedures</span><span class="headingEndMark"> — </span>For most patients who are at low or moderate risk for thrombosis, anticoagulation can be safely discontinued prior to endoscopic procedure with either high bleeding risk or uncertain bleeding risk (eg, screening colonoscopy)  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>). (See <a class="local">'Estimate bleeding risk'</a> above.) </p><p>The approach to interruption and resumption of anticoagulation depends on the agent used, as discussed below.</p><p class="headingAnchor" id="H4266859722"><span class="h4">Patients on warfarin</span><span class="headingEndMark"> — </span>For low to moderate risk patients on vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>), we use the following approach [<a href="#rid7">7</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> five days prior to the procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Confirm that INR is ≤1.5 on the day before or the day of the procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Restart <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> on the evening of the day of the procedure if hemostasis is achieved, as determined by the endoscopist. Special consideration is warranted for patients who have endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy. (See <a class="local">'Patients who undergo sphincterotomy'</a> below.) </p><p></p><p>Bridging therapy with a heparin product is generally not needed for low-risk patients because they are at low risk for a thromboembolic event with temporary interruption of anticoagulation. The decision to use bridging therapy involves balancing the risk of a thromboembolic event with the risk of procedure-related bleeding, and this is discussed separately. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p class="headingAnchor" id="H3520257220"><span class="h4">Patients on direct oral anticoagulants</span><span class="headingEndMark"> — </span>For low to moderate risk patients taking an oral direct thrombin or factor Xa inhibitor (eg, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) with normal renal function, our approach is the following (see  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Discontinue the drug 48 hours prior to the procedure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>After the procedure, wait 48 hours before the restarting the drug if hemostasis is achieved, as determined by the endoscopist. Special consideration is warranted for patients who have ERCP with sphincterotomy. (See <a class="local">'Patients who undergo sphincterotomy'</a> below.) </p><p></p><p>Preprocedure medication adjustments for patients with renal insufficiency are discussed below. (See <a class="local">'Patients with renal insufficiency on direct oral anticoagulants (DOACs)'</a> below.) </p><p>These drugs have rapid onsets of action (one to three hours) and short half-lives (5 to 17 hours, depending on agent, in patients with normal renal function) [<a href="#rid10">10</a>]. The full anticoagulant effect of direct oral anticoagulants (DOACs) occurs within hours of administration, and for this reason we wait 48 hours prior to restarting a DOAC because of the risk of immediate post-procedure bleeding.</p><p class="headingAnchor" id="H2796393357"><span class="h4">Patients who undergo sphincterotomy</span><span class="headingEndMark"> — </span>Because of the increased risk of bleeding, we delay restarting anticoagulation after ERCP with sphincterotomy:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> – Restart warfarin in three days</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on DOACs</strong> – Restart DOACs in five days</p><p></p><p>The risk of bleeding following biliary or pancreatic sphincterotomy persists for three to five days after the procedure. For patients at low or moderate risk for thrombosis, it is reasonable to delay attaining therapeutic levels (for those receiving <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) or the full effect of anticoagulation (for those receiving DOACs) until five days following the procedure [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Patients with high thrombotic risk</span><span class="headingEndMark"> — </span>Patients at high risk for thromboembolic events include patients with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation with CHA<sub>2</sub>DS<sub>2</sub>-VASc score ≥4 (CHADS<sub>2</sub> score of ≥3)  (<a class="graphic graphic_table graphicRef94752" href="/d/graphic/94752.html" rel="external">table 3</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation with stroke or transient ischemic attack within three months </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rheumatic valvular heart disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Venous thromboembolism within 12 months</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thrombophilia (eg, antiphospholipid antibodies, heterozygous factor V Leiden, prothrombin gene mutation)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent venous thromboembolism</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Active cancer (treated within six months or palliative)</p><p></p><p>Patients with certain prosthetic heart valves are also at high thrombotic risk; preprocedural anticoagulation management for these patients is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p class="headingAnchor" id="H3610754384"><span class="h3">Low-risk procedures</span><span class="headingEndMark"> — </span>Patients at high risk for thromboembolic events require no change in anticoagulation prior to low-risk procedures  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>), (eg, upper gastrointestinal endoscopy EGD or colonoscopy, with or without mucosal biopsy). (See  <a class="medical medical_review" href="/d/html/2671.html" rel="external">"Management and prevention of bleeding after colonoscopy with polypectomy", section on 'Immediate bleeding'</a>.)</p><p>For patients taking vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>), we prefer an INR ≤2.5 prior to low-risk, elective procedures. The threshold INR value is based on indirect data in patients undergoing endoscopic procedures for active bleeding and personal preference, and other experts may use different thresholds. (See <a class="local">'Patients on warfarin'</a> below.) </p><p class="headingAnchor" id="H2644075154"><span class="h3">High-risk procedures</span></p><p class="headingAnchor" id="H3907240008"><span class="h4">Patients on warfarin</span><span class="headingEndMark"> — </span>High-risk procedures generally warrant interruption of anticoagulation. For patients who are at high risk for thromboembolism and who are undergoing high- risk procedures  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>), we ask the clinician who is managing the patient’s anticoagulation if it is safe to hold <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> for five days prior to the procedure and if bridging therapy is needed. Warfarin should be discontinued such that the INR is ≤ 1.5 by the day of the procedure.</p><p>The need for bridging anticoagulation (ie, use of a short-acting anticoagulant during the interruption of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) is generally determined by the magnitude of the patient’s thrombotic risk. For example, a condition that confers a very high risk of thromboembolism and generally necessitates bridge therapy is atrial fibrillation with CHA<sub>2</sub>DS<sub>2</sub>-VASc score of ≥5. If bridging therapy is warranted, it may be indicated preoperatively, postoperatively, or both. Heparin products (low molecular weight heparin or <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a>) are used for bridging anticoagulation. The approach to selecting patients for bridge therapy and the administration and dosing of bridge therapy are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a>.)</p><p>The intent of bridging is to minimize the time the patient is not anticoagulated, thereby minimizing the risk for perioperative thromboembolism. However, this needs to be balanced with the importance of mitigating the risk of postoperative bleeding. A slight delay in resumption of postoperative anticoagulation is preferable to premature initiation of postoperative bridging and/or long-term anticoagulation that results in bleeding, which ultimately will lengthen the period without an anticoagulant and thus increase thromboembolic risk.</p><p>In general, anticoagulation may be resumed after hemostasis is achieved after a high risk intervention that has a low risk of rebleeding (as determined by the endoscopist). </p><p>The time interval prior to resuming anticoagulation also depends on the specific lesion, specific intervention, accessibility of the endoscopic site, and degree of difficulty required to achieve hemostasis. Examples of anticoagulation management following common high-risk procedures include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polypectomy of colon polyp ≥1 cm – </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">Warfarin</a> is resumed in the evening of the day of the procedure since it takes several days to achieve a therapeutic effect. For those receiving bridge therapy, low molecular weight heparin at therapeutic doses can generally be resumed 48 hours after colonoscopic polypectomy. Endoscopic methods that may help lower the risk of postpolypectomy bleeding, including placement of hemoclips, are discussed separately. (See  <a class="medical medical_review" href="/d/html/2577.html" rel="external">"Endoscopic removal of large colon polyps", section on 'Preventing bleeding'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sphincterotomy – </strong>For patients who undergo biliary or pancreatic sphincterotomy, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> is not restarted until 72 hours after endoscopic retrograde cholangiopancreatography (ERCP) because of the risk of postsphincterotomy bleeding. For those who are receiving bridge therapy, <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> may be started 24 to 48 hours after ERCP with sphincterotomy. We prefer unfractionated heparin because of its short half-life. (See  <a class="medical medical_review" href="/d/html/636.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding"</a>.) </p><p></p><p class="headingAnchor" id="H571388889"><span class="h4">Patients on direct oral anticoagulants</span><span class="headingEndMark"> — </span>We confirm with the clinician managing anticoagulation that it is acceptable to temporarily discontinue the DOAC, and periprocedural management of these high-risk patients is similar to the approach for low- to moderate-risk patients, as described above. (See <a class="local">'Patients on direct oral anticoagulants'</a> above and <a class="local">'Specialty consultation'</a> above.)</p><p>Bridging therapy for patients on DOACs is not required given their short half-lives. </p><p class="headingAnchor" id="H1214469485"><span class="h3">Procedures with uncertain risk</span><span class="headingEndMark"> — </span>For some procedures (eg, screening colonoscopy), the preprocedure estimate of bleeding risk is uncertain because it is unknown whether a high-risk intervention (eg, polypectomy of large polyp [≥1 cm]) will be necessary. For most high-risk patients undergoing screening colonoscopy, we perform an initial colonoscopy without interrupting long-term anticoagulation, similar to our approach for a low-risk procedure. (See <a class="local">'Low-risk procedures'</a> above.)</p><p>If a large polyp requiring polypectomy is found, a second colonoscopy can be performed at a later date, with anticoagulant management similar to that for a high-risk procedure. (See <a class="local">'High-risk procedures'</a> above.)</p><p>The decision of whether to proceed in this manner or to discontinue anticoagulation and provide bridging therapy when the need for high-risk intervention is uncertain requires shared decision-making between the patient and physician. An alternative approach is to manage the patient as if the colonoscopy will include a high-risk intervention. The advantage of this approach is that if a large polyp is found, it can be removed at the index colonoscopy. The disadvantage is that some high-risk patients will have to discontinue anticoagulation when interruption was not necessary.</p><p class="headingAnchor" id="H3377953318"><span class="h2">Patients with transient thrombotic risk</span><span class="headingEndMark"> — </span>If thromboembolic risk is transiently increased (eg, deep venous thrombosis), we prefer to delay an elective endoscopic procedure until the risk returns to baseline. </p><p class="headingAnchor" id="H12"><span class="h1">URGENT PROCEDURES</span></p><p class="headingAnchor" id="H13"><span class="h2">Patients with bleeding</span><span class="headingEndMark"> — </span>For patients with active gastrointestinal bleeding, the risk of reversing anticoagulation should be weighed against the risk of continued bleeding without reversal [<a href="#rid1">1</a>]. In addition, the course of action depends on the antithrombotic agent. (See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults"</a> and  <a class="medical medical_review" href="/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults"</a>.)</p><p class="headingAnchor" id="H874273945"><span class="h3">Patients on warfarin</span><span class="headingEndMark"> — </span>Patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> with serious or life-threatening bleeding require rapid, full reversal of any warfarin effect, whereas those with minor bleeding may be best served by holding warfarin without administration of a reversal agent. </p><p>For patients with life-threatening hemorrhage, fresh frozen plasma (FFP), and unactivated prothrombin complex concentrate (PCC) can be used to reverse anticoagulation from <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>  (<a class="graphic graphic_table graphicRef89478" href="/d/graphic/89478.html" rel="external">table 4A</a>). FFP is used for most patients. However, PCC is preferred in patients with variceal bleeding or those at risk for cardiac failure, because the volume of FFP may increase portal pressure and precipitate cardiac failure. Vitamin K is less useful than FFP or PCC in the acute setting because of its delayed onset of action (12 to 24 hours). The approach to managing a patient with warfarin-associated bleeding is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1324.html" rel="external">"Management of warfarin-associated bleeding or supratherapeutic INR", section on 'Treatment of bleeding'</a>.) </p><p>Once reversal of anticoagulation has been initiated, the target international normalized ratio (INR) prior to an endoscopic intervention is based on endoscopist’s preference. Limited data suggest that an endoscopic intervention will be successful within a range of target INRs. Some UpToDate contributors prefer an INR of ≤1.5 prior to a high-risk procedure, while other contributors proceed with the intervention when the INR is ≤2.5 and then continue to reverse anticoagulation or let the INR naturally decline to ≤1.5 for at least 72 hours after endoscopic therapy. The American Society for Gastrointestinal Endoscopy suggests that endoscopic therapy not be delayed in patients with an INR &lt;2.5 and serious gastrointestinal bleeding [<a href="#rid1">1</a>]. Of note, endoscopic therapy for any actively bleeding lesion is regarded as a high-risk procedure  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>).</p><p>Data from observational studies suggest that the success rates of endoscopic therapy for gastrointestinal bleeding in patients who are mildly to moderately anticoagulated (INRs of 1.3 to 2.7) are comparable to the success rates in patients who are not anticoagulated [<a href="#rid12">12-14</a>]. In one report, successful hemostasis was achieved with endoscopic therapy in 91 percent of 52 patients with acute upper gastrointestinal (GI) bleeding after correcting the INR to 1.5 to 2.5, a success rate comparable to a control population of patients who were not anticoagulated [<a href="#rid12">12</a>]. The distribution of patients’ INR values within the goal range was not provided. Outcome data are lacking for patients with INRs above the therapeutic range (≥4.0) who undergo urgent endoscopic intervention.</p><p class="headingAnchor" id="H168146289"><span class="h3">Patients on direct oral anticoagulants</span><span class="headingEndMark"> — </span>The approach to patients on direct oral anticoagulants (DOAC) therapy with acute gastrointestinal bleeding depends on the severity of the bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Severe, life-threatening bleeding -</strong> For patients with severe, life-threatening gastrointestinal bleeding, strategies for reversing the effects of DOACs include  (<a class="graphic graphic_table graphicRef96230" href="/d/graphic/96230.html" rel="external">table 4B</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use a specific reversal agent, if available. Specific reversal agents are approved for use for <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> (<a class="drug drug_general" data-topicid="104819" href="/d/drug information/104819.html" rel="external">idarucizumab</a>) and for the oral direct factor Xa inhibitors (<a class="drug drug_general" data-topicid="117811" href="/d/drug information/117811.html" rel="external">andexanet alfa</a>) [<a href="#rid15">15,16</a>]. However, andexanet alfa (reversal agent for <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> or <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>) is not yet widely available [<a href="#rid16">16</a>]. The onset of action of the reversal agents is approximately two to four hours. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use a nonspecific reversal agent (eg, prothrombin complex concentrates, which are prothrombotic).</p><p></p><p class="bulletIndent1">The approach to selecting a strategy for reversing the effects of DOACs in patients with major bleeding is presented separately. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Major bleeding'</a>.) Patients are monitored clinically since routine coagulation testing cannot be used as evidence that the DOAC effect has been reversed. The specific reversal agents for DOACs typically take effect within minutes of administration. (See  <a class="medical medical_review" href="/d/html/94788.html" rel="external">"Management of bleeding in patients receiving direct oral anticoagulants", section on 'Assessment of anticoagulation status'</a>.)</p><p></p><p class="bulletIndent1">We proceed with urgent endoscopy with possible therapeutic intervention following administration of the nonspecific and/or specific reversal agents, if available. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonsevere bleeding</strong> – For most patients with nonsevere but active gastrointestinal bleeding, the DOAC is held while the patient receives general supportive measures, fluid resuscitation, and transfusion of blood products if needed. Because of the relatively short half-lives for these drugs (5 to 17 hours, depending on agent), the anticoagulation effect is relatively short-lived in patients with normal renal function. (See  <a class="medical medical_review" href="/d/html/2547.html" rel="external">"Approach to acute lower gastrointestinal bleeding in adults", section on 'Initial management'</a> and  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'General management'</a>.) </p><p></p><p class="bulletIndent1">For patients who are hemodynamically stable following resuscitation, endoscopic evaluation can typically be performed within 12 to 24 hours because the DOAC effect has diminished [<a href="#rid4">4</a>]. In addition, bleeding may stop without endoscopic intervention for some patients, although most patients undergo endoscopy to evaluate the source of bleeding [<a href="#rid10">10</a>]. </p><p></p><p class="headingAnchor" id="H15"><span class="h3">Resuming anticoagulants after hemostasis</span></p><p class="headingAnchor" id="H154347528"><span class="h4">Patients with low rebleeding risk</span><span class="headingEndMark"> — </span>We generally restart anticoagulation after hemostasis has been achieved for hemodynamically stable patients who have lesions with low-risk of rebleeding (eg, duodenal ulcer with a clean base)  (<a class="graphic graphic_table graphicRef78607" href="/d/graphic/78607.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers", section on 'Stigmata of recent hemorrhage'</a>.)</p><p>The approach to and timing for restarting anticoagulation following hemostasis depends on the specific anticoagulant and if bridging is required:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on </strong><a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a><strong> -</strong> We restart warfarin in the evening of the procedure day, if no further bleeding occurs. Patients who resume warfarin will require several days to achieve therapeutic levels of anticoagulation. </p><p></p><p class="bulletIndent1">For those patients who had high enough thrombotic risk to warrant bridge therapy, we restart intravenous <a class="drug drug_general" data-topicid="8518" href="/d/drug information/8518.html" rel="external">unfractionated heparin</a> 48 hours after hemostasis is achieved for patients who require bridge therapy. Initial postprocedure anticoagulation with intravenous unfractionated heparin is preferable to low molecular weight heparin (which is typically used in patients who have undergone surgery) due to its relatively short half-life of 1.5 hours [<a href="#rid1">1</a>]. This allows for quick reversal following discontinuation of unfractionated heparin if bleeding recurs. (See <a class="local">'Patients with high thrombotic risk'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients on DOACs</strong> – We restart DOACs 48 to 72 hours after hemostasis has been achieved, if no further bleeding occurs. Administration of DOACs (<a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) results in therapeutic levels of anticoagulation within one to three hours of administration [<a href="#rid10">10</a>]. </p><p></p><p>A detailed approach to resuming DOACs, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> and/or using bridging therapy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Bridging anticoagulation'</a> and  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Timing of anticoagulant interruption'</a>.) </p><p>Studies suggest that patients who resume anticoagulation have better outcomes compared with those who remain without long-term anticoagulation [<a href="#rid17">17-20</a>]. In a meta-analysis of three studies including over 1800 patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> with gastrointestinal bleeding, patients who resumed warfarin following interruption were less likely to have thromboembolic events (HR 0.68, 95% CI 0.52-0.88) or to die (HR 0.76, 95% CI 0.66-0.88) [<a href="#rid19">19</a>]. There was a trend toward an increase in the risk of rebleeding (HR 1.20, 95% CI 0.97-1.48). </p><p>Subsequent observational studies have demonstrated similar findings [<a href="#rid18">18,20</a>]. In a cohort study of 4602 anticoagulated patients with atrial fibrillation and GI bleeding, patients who resumed an oral anticoagulant had lower rate of all-cause mortality and thromboembolism compared with patients who did not resume treatment (HR 0.39, 95% CI 0.34-0.46 and HR 0.41, 95% CI 0.31-0.54, respectively) [<a href="#rid20">20</a>]. </p><p>Data are limited with regard to the specific timing for resuming anticoagulation for patients who are recovering from an episode of GI bleeding. In one study, the median time to resumption of <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a> was four days (range two to nine days) [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H333961552"><span class="h4">Patients with high rebleeding risk</span><span class="headingEndMark"> — </span>For patients with lesions at high risk of rebleeding, we delay restarting anticoagulation (if possible, depending on the patient’s thrombotic risk) until the rebleeding risk is lower. (See <a class="local">'Patients with low rebleeding risk'</a> above.)</p><p>The duration of the delay is based on several factors, including the source and location of bleeding, the endoscopic method used to achieve hemostasis, the hemodynamic status of the patient, and the potential consequences of rebleeding (eg, need for surgical intervention). Risk factors associated with rebleeding and the natural history of specific gastrointestinal lesions are discussed in various UpToDate topics on gastrointestinal bleeding:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2573.html" rel="external">"Overview of the treatment of bleeding peptic ulcers", section on 'Risk factors for persistent or recurrent bleeding'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Risk stratification'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1260.html" rel="external">"Methods to achieve hemostasis in patients with acute variceal hemorrhage", section on 'Natural history and prognosis with treatment'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2641.html" rel="external">"Colonic diverticular bleeding", section on 'Risk of rebleeding and complications'</a>.)</p><p></p><p class="headingAnchor" id="H2607225778"><span class="h2">Patients without bleeding</span><span class="headingEndMark"> — </span>When urgent endoscopic procedures are required in anticoagulated patients who are not actively bleeding (eg, patients with acute cholangitis from biliary obstruction), management options include a temporary, low risk endoscopic intervention (ie, biliary stent without sphincterotomy) in order to delay the need for a procedure that carries a high risk of bleeding  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/d/html/636.html" rel="external">"Post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding", section on 'Preventive strategies'</a>.)</p><p>If a high-risk endoscopic intervention cannot be delayed, agents that quickly reverse anticoagulation can be administered if the risk of bleeding outweighs the risk of thrombotic events. The management of anticoagulated patients who need an urgent, high-risk endoscopic intervention for conditions other than gastrointestinal bleeding (eg, acute cholangitis) is similar to the management of patients who need urgent endoscopic treatment for bleeding. (See <a class="local">'Patients with bleeding'</a> above.) </p><p class="headingAnchor" id="H3459979831"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H815457141"><span class="h2">Patients with prosthetic heart valves</span><span class="headingEndMark"> — </span>Anticoagulation management for patients with prosthetic heart valves is discussed separately. (See  <a class="medical medical_review" href="/d/html/104830.html" rel="external">"Anticoagulation for prosthetic heart valves: Management of bleeding and invasive procedures"</a>.)</p><p class="headingAnchor" id="H1745371527"><span class="h2">Patients with renal insufficiency on direct oral anticoagulants (DOACs)</span><span class="headingEndMark"> — </span>Patients with renal insufficiency who take DOACs require a longer discontinuation period prior to high-risk endoscopic procedures. </p><p>Because of the predominantly renal excretion (&gt;80 percent) of <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, the hold time varies depending on the patient's creatinine clearance (CrCl):</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl 30 to 49 mL/min: Hold <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> for at least three days prior to the procedure</p><p class="bulletIndent1"><span class="glyph">●</span>CrCl &lt;30 mL/min (ie, drug half-life is &gt;24 hours): Hold <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a> for at least five to seven days prior to the procedure</p><p></p><p>Because other DOACs (ie, <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a> and <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>) have ≤50 percent renal excretion, special dose adjustment is needed only for patients with severe renal impairment (CrCl&lt;30 mL/min). These DOACs are held for two to three days prior to high-risk procedures in such patients [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H4155004692"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120175.html" rel="external">"Society guideline links: Endoscopy preparation, sedation, and special considerations"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General principles –</strong> The probability of a thromboembolic complication following reversal or discontinuation of anticoagulation depends upon the preexisting condition for which the medication was prescribed  (<a class="graphic graphic_table graphicRef86930" href="/d/graphic/86930.html" rel="external">table 1</a>). (See <a class="local">'Estimate thromboembolic risk'</a> above and  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants", section on 'Estimating thromboembolic risk'</a>.)</p><p></p><p class="bulletIndent1">The risk of bleeding from endoscopic procedures can be classified as low or high. In general, diagnostic procedures are low risk, whereas therapeutic procedures are high risk  (<a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>). (See <a class="local">'Estimate bleeding risk'</a> above and  <a class="medical medical_review" href="/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Estimating procedure-related bleeding risk'</a>.)</p><p></p><p class="bulletIndent1">We consult with the clinician and/or clinical service who are managing the patient’s long-term anticoagulation (eg, cardiologist, neurologist, anticoagulation clinic) prior to electively interrupting anticoagulation therapy. (See <a class="local">'Specialty consultation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elective procedures</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Preprocedure management – </strong>Most patients require no interruption in anticoagulation prior to low-risk procedures  (<a class="graphic graphic_algorithm graphicRef119161" href="/d/graphic/119161.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef50700" href="/d/graphic/50700.html" rel="external">table 2</a>). For patients taking vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>), we confirm that the international normalized ratio (INR) is ≤2.5 prior to low risk, elective procedures. We suggest delaying the procedure until it is below that threshold (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Low risk procedures'</a> above.)</p><p></p><p class="bulletIndent2">In patients undergoing high-risk endoscopic procedures, we discontinue long-term anticoagulation  (<a class="graphic graphic_algorithm graphicRef119161" href="/d/graphic/119161.html" rel="external">algorithm 1</a>). Vitamin K antagonists (eg, <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>) are discontinued five days before a high-risk procedure, and direct oral anticoagulants (eg, <a class="drug drug_general" data-topicid="8926" href="/d/drug information/8926.html" rel="external">dabigatran</a>, <a class="drug drug_general" data-topicid="9498" href="/d/drug information/9498.html" rel="external">rivaroxaban</a>, <a class="drug drug_general" data-topicid="85642" href="/d/drug information/85642.html" rel="external">apixaban</a>, or <a class="drug drug_general" data-topicid="99275" href="/d/drug information/99275.html" rel="external">edoxaban</a>) are discontinued one to two days before a high-risk procedure in patients with normal renal function. While warfarin is held for high-risk procedures, indications for bridging anticoagulation with a heparin product before and after the procedure depends on the patient’s risk of thromboembolism. Bridging anticoagulation is not necessary for patients at low risk for thromboembolism, but may be warranted in certain high-risk patients. (See <a class="local">'High or uncertain risk procedures'</a> above and  <a class="medical medical_review" href="/d/html/1312.html" rel="external">"Perioperative management of patients receiving anticoagulants"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Resuming anticoagulation</strong> <strong>–</strong> The time interval prior to resuming anticoagulation depends on the specific lesion, specific intervention, accessibility of the endoscopic site, and degree of difficulty that was required to achieve hemostasis  (<a class="graphic graphic_algorithm graphicRef119161" href="/d/graphic/119161.html" rel="external">algorithm 1</a>). (See <a class="local">'High-risk procedures'</a> above and <a class="local">'High or uncertain risk procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urgent procedures –</strong> For patients with gastrointestinal bleeding, the risk of reversing anticoagulation should be weighed against the risk of continued bleeding without reversal. Anticoagulants are held in patients with acute gastrointestinal bleeding, while the use of reversal agents depends on the severity of bleeding, the characteristics of the specific anticoagulant (eg, half-life), and the availability of the reversal agent  (<a class="graphic graphic_table graphicRef89478 graphicRef96230" href="/d/graphic/89478.html" rel="external">table 4A-B</a>). For patients on <a class="drug drug_general" data-topicid="10050" href="/d/drug information/10050.html" rel="external">warfarin</a>, we proceed with nonelective endoscopy when the target INR ranges between 1.5 and 2.5, based on limited data and the endoscopist’s preference. (See <a class="local">'Urgent procedures'</a> above.)</p><p></p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ASGE Standards of Practice Committee, Acosta RD, Abraham NS, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016; 83:3.</a></li><li><a class="nounderline abstract_t">Becker RC, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J Am Coll Cardiol 2009; 54:2261.</a></li><li><a class="nounderline abstract_t">Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e326S.</a></li><li><a class="nounderline abstract_t">Barkun AN, Almadi M, Kuipers EJ, et al. Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group. Ann Intern Med 2019; 171:805.</a></li><li><a class="nounderline abstract_t">Veitch AM, Radaelli F, Alikhan R, et al. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy 2021; 53:947.</a></li><li><a class="nounderline abstract_t">Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. Am J Gastroenterol 2022; 117:542.</a></li><li><a class="nounderline abstract_t">Baron TH, Kamath PS, McBane RD. Management of antithrombotic therapy in patients undergoing invasive procedures. N Engl J Med 2013; 368:2113.</a></li><li><a class="nounderline abstract_t">Baron TH, Kamath PS, McBane RD. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol 2014; 12:187.</a></li><li><a class="nounderline abstract_t">Gallego P, Apostolakis S, Lip GY. Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation. Circulation 2012; 126:1573.</a></li><li><a class="nounderline abstract_t">Desai J, Granger CB, Weitz JI, Aisenberg J. Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc 2013; 78:227.</a></li><li><a class="nounderline abstract_t">Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996; 335:909.</a></li><li><a class="nounderline abstract_t">Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994; 35:464.</a></li><li><a class="nounderline abstract_t">Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003; 58:369.</a></li><li><a class="nounderline abstract_t">Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007; 102:290.</a></li><li class="breakAll">http://www.drugs.com/history/praxbind.html (Accessed on November 12, 2015).</li><li class="breakAll">https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM606687.pdf (Accessed on May 07, 2018).</li><li><a class="nounderline abstract_t">Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012; 172:1484.</a></li><li><a class="nounderline abstract_t">Sengupta N, Feuerstein JD, Patwardhan VR, et al. The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study. Am J Gastroenterol 2015; 110:328.</a></li><li><a class="nounderline abstract_t">Chai-Adisaksopha C, Hillis C, Monreal M, et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis. Thromb Haemost 2015; 114:819.</a></li><li><a class="nounderline abstract_t">Staerk L, Lip GY, Olesen JB, et al. Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ 2015; 351:h5876.</a></li></ol></div><div id="topicVersionRevision">Topic 2609 Version 38.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26621548" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The management of antithrombotic agents for patients undergoing GI endoscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19942393" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315266" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31634917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34359080" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35297395" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23718166" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Management of antithrombotic therapy in patients undergoing invasive procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23735447" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : New anticoagulant and antiplatelet agents: a primer for the gastroenterologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008469" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23725876" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Novel oral anticoagulants in gastroenterology practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8782497" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Complications of endoscopic biliary sphincterotomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8174982" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14528210" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100959" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100959" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17100959" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22987143" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25512338" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26018236" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26572685" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
